Key Takeaways
- Shares of AbCellera surged 32% to reach $9.12 following positive Phase 2 clinical trial data for menopause treatment ABCL635
- Trial participants receiving a single 600mg injection experienced an 8.8 daily reduction in hot flashes compared to 3.5 for those on placebo
- Patients reported meaningful improvements in symptom severity and sleep quality throughout the study period
- The randomized, double-blind, placebo-controlled study included 92 postmenopausal women experiencing frequent hot flashes
- The four-week treatment period showed favorable tolerability with zero serious adverse events documented
Shares of AbCellera (ABCL) experienced a dramatic 32% surge to $9.12 during Monday’s trading session following the announcement of encouraging Phase 2 clinical trial outcomes for its investigational menopause therapy.
AbCellera Biologics Inc., ABCL
Prior to Monday’s rally, the stock had already experienced substantial gains throughout 2026, with much of that momentum building around investor expectations for this critical data release.
The investigational compound ABCL635 represents a non-hormonal, extended-duration therapy administered through a single subcutaneous injection. The drug works by targeting the neurokinin 3 receptor, a biological pathway implicated in the onset of vasomotor symptoms.
The Phase 2 clinical study recruited 92 postmenopausal women suffering from approximately 10 moderate to severe vasomotor episodes daily. Study participants were randomly assigned to receive either a single 600mg subcutaneous administration of ABCL635 or an inactive placebo injection.
At the four-week mark, the study successfully achieved its primary efficacy measures. This indicates the therapy reached the predetermined statistical benchmarks required for the company to declare the trial successful.
Trial Results Breakdown
Regarding vasomotor episode frequency, patients treated with ABCL635 experienced an 8.8 event-per-day decline in moderate-to-severe hot flashes from their starting baseline. Participants receiving placebo showed a 3.5 event reduction. This translates to a placebo-adjusted benefit of 5.3 fewer daily episodes.
Examining symptom intensity, the investigational therapy reduced severity scores by 1.4 points at the four-week assessment versus 0.3 points in the placebo arm, yielding a placebo-adjusted improvement of 1.1 points.
Women receiving ABCL635 additionally experienced enhanced sleep quality and reported feeling better overall, as measured by patient global impression of change assessments.
The study employed a randomized, double-blind, placebo-controlled methodology, representing the gold standard clinical trial framework for this category of research.
Tolerability Data
ABCL635 demonstrated favorable tolerability throughout the four-week observation window. Researchers documented zero serious adverse events, zero severe adverse events, and no participant withdrawals attributed to treatment-related side effects.
The side effects most frequently observed among ABCL635 recipients included headache, fatigue, and localized reactions at the injection site.
AbCellera convened a conference call Monday to review the clinical findings with the investment community and research analysts.
Management is highlighting ABCL635 as a hormone-free alternative, which may prove valuable for women who are unable to use or choose to avoid hormone replacement therapies.
ABCL stock finished Monday’s session at $9.12, representing a 32% single-day gain.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
